Snipr Biome reported first patient data indicating a positive effect from SNIPR-001, a CRISPR-modified bacteriophage targeting antibiotic-resistant Escherichia coli. The data were described as coming from a single patient treated under an emergency investigational new drug application. Snipr said it recently completed recruitment to a Phase Ib/IIa trial to prevent bloodstream infections in patients with hematological cancers, but the emergency-treatment data provide early clinical evidence ahead of broader enrollment outcomes. The company’s strategy combines phage therapy with CRISPR engineering to enhance targeting against difficult bacterial strains, aiming to address unmet needs amid persistent antibiotic resistance. For the broader biopharma community, the announcement highlights how precision biologics approaches—here, engineered phages—are entering clinical testing with rapidly accumulating early signals that may shape future trial design and dosing strategies.